Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Journal of Medicinal Chemistry|April 15, 2020
Design, Synthesis, and Biological Evaluation of New Peripheral 5HT2A Antagonists for Nonalcoholic Fatty Liver DiseaseMinhee Kim, Inseon Hwang, Haushabhau S Pagire, et al.European Journal of Medicinal Chemistry|August 8, 2020
An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancerJina Kim, Hayoung Hwang, Heeseok Yoon, et al.Nature Communications|January 20, 2024
Discovery of a peripheral 5HT2A antagonist as a clinical candidate for metabolic dysfunction-associated steatohepatitisHaushabhau S Pagire, Suvarna H Pagire, Byung-Kwan Jeong, et al.European Journal of Medicinal Chemistry|May 29, 2016
Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonistsJina Kim, Jungwook Chin, Chun Young Im, et al.Proceedings of the National Academy of Sciences of the United States of America|May 8, 2023
Upregulation of the ERRγ-VDAC1 axis underlies the molecular pathogenesis of pancreatitisDipanjan Chanda, Themis Thoudam, Ibotombi Singh Sinam, et al.Diabetes|July 8, 2016
Inhibition of Pyruvate Dehydrogenase Kinase 2 Protects Against Hepatic Steatosis Through Modulation of Tricarboxylic Acid Cycle Anaplerosis and KetogenesisYounghoon Go, Ji Yun Jeong, Nam Ho Jeoung, et al.Kidney International|July 3, 2023
Inhibition of pyruvate dehydrogenase kinase 4 ameliorates kidney ischemia-reperfusion injury by reducing succinate accumulation during ischemia and preserving mitochondrial function during reperfusionChang Joo Oh, Min-Ji Kim, Ji-Min Lee, et al.Journal of Medicinal Chemistry|November 3, 2016
Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse AgonistsJina Kim, Seo Yeon Woo, Chun Young Im, et al.Journal of Medicinal Chemistry|January 10, 2019
Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic DiseasesDahye Lee, Haushabhau S Pagire, Suvarna H Pagire, et al.Nature Communications|March 27, 2023
Enhanced Ca2+-channeling complex formation at the ER-mitochondria interface underlies the pathogenesis of alcohol-associated liver diseaseThemis Thoudam, Dipanjan Chanda, Jung Yi Lee, et al.Pageof 10